Catheter for mapping of complex cardiac arrhythmias launched
Click Here to Manage Email Alerts
Key takeaways:
- A catheter for mapping complex cardiac arrhythmias has been launched in the U.S.
- The product could help electrophysiologists identify ablation targets faster.
Biosense Webster announced the U.S. launch of a catheter to help electrophysiologists with mapping complex cardiac arrhythmias.
The catheter (Optrell Mapping Catheter with TrueRef Technology) received FDA clearance in 2022, according to a press release from the company.
Image: Adobe Stock
The catheter has small electrodes in a fixed array formation to facilitate high-definition mapping of complex cardiac arrhythmias such as persistent atrial fibrillation, redo AF, atrial tachycardia and ventricular tachycardia, the company stated in the release.
The product is intended for use with a system (Carto 3, Biosense Webster) that provides local conduction vectors to help electrophysiologists determine the real-time direction and speed of the heart’s electrical impulses, according to the release.
“The Optrell Mapping Catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets,” Pasquale Santangeli, MD, PhD, associate section head and director of the ventricular tachycardia (VT) program in the Cardiac Electrophysiology and Pacing Section of the Tomsich Family Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, said in the release. “This catheter and the local conduction vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia and ventricular tachycardia.”
Collapse
Click Here to Manage Email Alerts